Table 1 Study design schedule
Period | Screening | Baseline | Treatment(w1-6) | Follow-up(w7-30) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week (W) | W- 1 | W0 | W2 | W3 | W4 | W6 | W15 | W16 | W17 | W18 | W27 | W28 | W29 | W30 |
Eligibility | X | |||||||||||||
Informed consent | X | |||||||||||||
Demography and medical history | X | |||||||||||||
Physical examination | X | |||||||||||||
Laboratory test | X | |||||||||||||
1-h pad test | X | X | X | |||||||||||
72-h bladder diary | X | X | X | X | X | X | X | X | X | X | X | X | ||
Weekly consumption of pads | X | X | X | X | X | X | X | X | X | X | X | X | ||
Application of other treatments for SUI | X | X | X | X | X | X | X | X | X | X | X | X | ||
ICIQ-UI Short form | X | X | X | X | ||||||||||
Self-report assessment of therapeutic effect | X | X | X | X | X | |||||||||
Safety of EA | X | X | X | |||||||||||
Discomfort and acceptance of EA | X | X | ||||||||||||
Assessment of blind method | X | X | ||||||||||||
Adverse event | X | X | X | X | X | X | X | X | X | X | ||||
Compliance | X | X | X | X | X | X | X | X | X | X | ||||